Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and RecommendationsLois B. Travis, Mark H. Greene, Colin B. Begg et al.|JNCI Journal of the National Cancer Institute|2006Cited by 344
Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 StudyGiuseppe Di Lorenzo, Sabino De Placido, William D. Figg et al.|European Urology|2008Cited by 128
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2‐methoxyestradiolNehal J. Lakhani, William D. Figg, Alex Sparreboom et al.|Journal of Pharmaceutical Sciences|2007Cited by 38